Main Article Content
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults,(1) effected a change in the paradigm of dyslipidaemia management, in that it no longer advocated a target based therapy but instead posited a primary clinical basis for initiation of statin therapy. The intensity of statin therapy too was guided by clinical risk criteria rather than by absolute values of the lipid profile.
Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129 (25 Suppl. 2):S1-45.
Reiner Z, Catapano AL, Graham I, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670– 81.
Catapano AL, Graham I, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37:2999-3058.
Anderson TJ, Gregoire J, Pearson GJ, et al. Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult.Canadian J Cardiol 2016;32:1263-82.
Wadhera RK, Steen DL, Khan I, et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 2015;10:472-89. doi: 10.1016/j.jacl.2015.11. 010.
Serban C, Muntean D, Mikhailids DP, et al. Dysfunctional HDL: the journey from savior to slayer. Clin Lipid 2014;9:49-59.49-59.